Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar added to insulin in type 2 diabetes
NCT00242372Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Tesaglitazar + Insulin with Placebo + Insulin (2 arms). Primary endpoint: Glycosylated Hemoglobin A1c at 24 weeks. Started Aug 2004; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00242372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242372.